

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

ANNOUNCEMENT

Guangzhou Pharmaceutical Company Limited (the “Company”) was informed on 12 August 2012 that Guangzhou Wang Lao Ji Great Health Industry Company Limited* (廣州王老吉大健康產業有限公司) (“WLJ Great Health”), the wholly-owned subsidiary of the Company, had received a notice calling for responses to civil legal proceedings [(2012) – Zhongminchuzi No. 8778] [(2012) – 中民初字第8778號] (the “Responses Notice”) from the Beijing No.1 Intermediate People’s Court* (北京市第一中級人民法院). According to the Responses Notice, the Beijing No.1 Intermediate People’s Court has accepted the submission made by the plaintiff, Guangdong Jia Duo Bao Beverage and Food Company Limited* (廣東加多寶飲料食品有限公司) (“Jia Duo Bao Company”) to proceed with the case in relation to the allegation of unauthorized use of the specific name, packaging and decoration of the well-known products by WLJ Great Health.

Furthermore, the Company has been informed that Guangzhou Pharmaceutical Holdings Limited (“GPHL”), the controlling shareholder of the Company, received a notice of case acceptance (Suizhongfaminsanchuzi No. 490) (穗中法民三初字第490號) (the “Acceptance Notice”) from the Guangzhou Intermediate People’s Court* (廣州市中級人民法院). According to the Acceptance Notice, the Guangzhou Intermediate People’s Court has accepted submission made by GPHL to proceed with the case in relation to the allegation of unauthorized use of the specific packaging and decoration of the well-known products by Hung To (Holdings) Company Limited* (鴻道(集團)有限公司) and Jia Duo Bao Company.

The board of the directors of the Company (the “Board”) confirms that, other than the Responses Notice and Acceptance Notice, it is not in possession of information which the Company is required to disclose under the Listing Rules of The Shanghai Stock Exchange and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Hong Kong Listing Rules”), nor is the Board aware of any information which may have any significant impact on the Company’s share price and is therefore discloseable under the Listing Rules of The Shanghai Stock Exchange or Hong Kong Listing Rules. The Company will closely monitor the progress of the events and fulfill its disclosure obligations on a timely basis.

The Company's designated media for publication of its information includes Shanghai Securities News, Securities Times, the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to pay attention to investment risks.

This announcement is made pursuant to Rules 13.09 (1) and 13.09 (2) of the Hong Kong Listing Rules.

The Board of
Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 14 August 2012

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.